Key Takeaways | ISO 13485 Compliance for Medical Device Companies

With FDA’s Quality Management System Regulation (QMSR) now in effect as of February 2, 2026, this webinar gave medical device manufacturers a clear, practical understanding of what the new rule requires and how to align their quality systems efficiently.

Key takeaways included:

1. ISO 13485:2016 is now central to US QMSR, but ISO certification alone doesn’t make you FDA-compliant. QMSR incorporates ISO 13485:2016 (and ISO 9000:2015 definitions), but companies must still comply with the full QMSR framework. FDA inspections still apply regardless of certification.
2. Expect “gap” areas where FDA requirements go beyond ISO 13485. Key US-specific overlays include requirements related to unique device identification (UDI), traceability, medical device reporting (MDR), device correction and removal reporting, and maintaining records of review, evaluation, and investigation complaints.
3. Inspections have shifted from QSIT checklists to a risk-driven CP 7832.50 model. QMSR officially retired the previous Quality System Inspection Technique (QSIT) and replaced it with the new Compliance Program Manual for Inspection of Medical Device Manufacturers (CP 7832.50). Investigators now begin with product risk signals (e.g., complaint trends, MDRs, recalls, field actions, servicing data) and trace through the Quality Management System (QMS) to test effectiveness.
4. Companies should confirm on-paper alignment to QSMR, reinforce risk management processes, and prepare for new FDA inspection expectations. Actionable next steps include verifying that QSMR transition work has been completed and terminology is consistent, validating that risk management files comply with ISO 13485 requirements, and leveraging mock inspections to assess readiness and proactively identify areas for improvement.